Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MR/W026279/1 | Other Grant/Funding Number | UKRI Medical Research Council | |
| 325120 | Other Identifier | IRAS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Glasgow | OTHER |
| University of Sheffield | OTHER |
| University of Newcastle Upon-Tyne | OTHER |
| University of Cambridge |
Not provided
Not provided
Not provided
The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH). The main question it aims to answer is whether structured changes in clinical therapy will be detectable using implanted regulatory approved devices. Participants will will be implanted with approved medical devices and will enter into a study of approved drugs to assess physiology, activity and patient reported quality-of-life (QoL) outcomes. Researchers will compare two therapeutic strategies in each individual patient to see if the study design provides enough evidence to personalise drug treatment plans
In this study, patients established on guideline recommended therapy will be implanted with devices and remote monitoring established. Patients will then enter into a 2x2 crossover study of approved drugs during which standard clinical investigations will be undertaken at baseline and maximal therapy on each drug. The cross-over design will provide multiple increases and decreases of drugs known to alter haemodynamics and 6MWT. The study is powered to detect improvement in right ventricular stroke volume measured by MRI from baseline to maximal therapy for each drug. It will then be established if changes in remote monitored measures provide an early indication of clinical efficacy when compared to the MRI, haemodynamics, NTproBNP and 6MWT made at 12-weeks. Remote measurement of haemodynamics during the two periods of de-escalation will inform understanding of physiology and inform clinical practice. The comparison of the two therapeutic strategies in individual patients in one study will facilitate novel clinical study designs and provide evidence for data-driven personalised medicine in the area.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A (selexipag/riociguat) | Active Comparator | Baseline - established PDE/ERA therapy Week 1 - initiate OPA (PDE/ERA/OPA therapy) Weeks 2-12 - uptitration of OPA to maximal therapy (PDE/ERA/OPA therapy) Weeks 13-14 - reduce OPA (PDE/ERA/OPA therapy) Week 15 - washout OPA (PDE/OPA therapy) Week 16 - washout PDE (ERA therapy) Week 17 - initiate sGCS (ERA/sGCS therapy) Weeks 18-27 - uptitration of sGCS to maximal therapy (ERA/sGCS therapy) |
|
| Arm B (riociguat/selexipag) | Active Comparator | Baseline - established PDE/ERA therapy Week 1 - washout PDE (ERA therapy only) Week 2 - initiate sGCS (ERA/sGCS therapy) Weeks 3-12 - uptitration of sGCS to maximal therapy (ERA/sGCS therapy) Week 13 - reduce sGCS (ERA/sGCS therapy) Week 14 - reduce and washout sGCS (ERA therapy) Week 15 - initiate PDE (PDE/ERA therapy) Week 16 - initiate OPA (PDE/ERA/OPA therapy) Weeks 17-27 - uptitration of OPA to maximal therapy (PDE/ERA/OPA therapy) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Selexipag | Drug | If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary. |
| Measure | Description | Time Frame |
|---|---|---|
| Right Ventricular Stroke Volume (RVSV) flow on each therapy measured by MRI RSVS (flow) on each therapy measured by MRI | This provides a robust, objective assessment of clinical efficacy which, if met, will mean that a change in therapy has provided a clinically meaningful change in physiology | Baseline to Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Haemodynamics - Total Pulmonary Resistance (TPR) | Change in TPR (Woods Units) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Haemodynamics - mean Pulmonary Artery Pressure (mPAP) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shravya Rao | Contact | +44 (0) 114 2159550 | s.rao@sheffield.ac.uk |
| Name | Affiliation | Role |
|---|---|---|
| Alexander Rothman, MD / PhD | University of Sheffield | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sheffield Teaching Hospitals NHS FT | Recruiting | Sheffield | S10 2JF | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33632769 | Background | Swift AJ, Wilson F, Cogliano M, Kendall L, Alandejani F, Alabed S, Hughes P, Shahin Y, Saunders L, Oram C, Capener D, Rothman A, Garg P, Johns C, Austin M, Macdonald A, Pickworth J, Hickey P, Condliffe R, Cahn A, Lawrie A, Wild JM, Kiely DG. Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. Thorax. 2021 Oct;76(10):1032-1035. doi: 10.1136/thoraxjnl-2020-216078. Epub 2021 Feb 25. |
Not provided
Not provided
Research samples will be transferred to the Sheffield Biorepository with no identifiable personal data.
Data will be collected and hosted and processed by University of Oxford (data supplier). Authorised data originators include, but are not limited to PIs and delegated staff; Participants; and Core Imaging Laboratory. The trial manager will lead the data verification process. Remote monitoring data will be managed through the Merlin.net system (Device supplier - Abbott). Pseudonymised data will then be transferred, held, analysed and archived securely at the University of Glasgow (processor). Data will also be transferred to the University of Sheffield and Newcastle University (processor) for study analysis.
The University of Sheffield shall own all right, title and interest in and to all of the University of Sheffield Data. For the purposes of the Data Protection Legislation, Sheffield Teaching Hospitals (sponsor) is the Data Controller.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000081029 | Pulmonary Arterial Hypertension |
| ID | Term |
|---|---|
| D006976 | Hypertension, Pulmonary |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C523468 | selexipag |
| C542595 | riociguat |
Not provided
Not provided
Not provided
| OTHER |
2x2 crossover study in which the effects of adding an oral drug targeting the prostacyclin pathway and the switching of PDE5i to sGCS will be examined following 12-weeks on treatment.
Not provided
Not provided
Not provided
Not provided
|
| Riociguat | Drug | If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary. |
|
|
| CardioMEMS pulmonary artery pressure monitor | Device | Implantation and remote monitoring established with patient initiated daily readings |
|
| Confirm Rx | Device | Implantation and remote monitoring established with automated daily readings / downloads |
|
Change in mPAP (mmHg) on each therapy to determine clinical efficacy |
| From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Haemodynamics - Cardiac Output (CO) | Change in CO (L/min) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Haemodynamics - Cardiac Index | Change in cardiac index (L/min/m^2) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Haemodynamics - Stroke Volume (SV) | Change in SV (mL) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Haemodynamics - Heart Rate (HR) | Change in HR (bpm) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| 6 Minute Walk Test | Change on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| NTpro-BNP | Change on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| MRI - Right Ventricular Ejection Fraction (RVEF) | RVEF (%) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| MRI - Right Ventricular End Systolic Volume (RVESV) | RVESV (mL/m^2) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| MRI - Right Ventricular End Diastolic Volume (RVEDV) | RVEDV (mL/m^2) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| MRI - Right Ventricular Stroke Volume (RVSV) | RVSV (mL) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| MRI - Left Ventricular Volume Fraction (LVEF) | LVEF (%) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| MRI - Left Ventricular End Systolic Volume (LVESV) | LVESV (mL/m^2) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| MRI - Left Ventricular End Diastolic Volume LVEDV | LVEDV (mL/m^2) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| MRI - Left Ventricular Stroke Volume (LVSV) | LVSV (mL) on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| MRI - Left Ventricular Stroke Volume (LVSV) flow | LVSV flow on each therapy to determine clinical efficacy | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Patient Reported Outcomes (PRO) - Quality of Life (QoL) (EmPHasis-10) | Change of QoL score on each therapy to determine clinical efficacy. This will be done using EmPHasis-10 questionnaire (10 questions using a 0 (poor) - 5 (good) scale) | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Patient Reported Outcomes (PRO) - Medication Compliance (PHoenix PRO) | Change of medication compliance score on each therapy to determine clinical efficacy. This will be done using PHoenix PRO questionnaire (10 questions using a 0 (poor) - 5 (good) scale) | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Patient Reported Outcomes (PRO) - Medication Side Effects | Change of medication side effects on each therapy to determine clinical efficacy. This will be done using PHoenix Medication side effects questionnaires (4 Yes/No or Better/Worse style questions) | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Patient Reported Outcomes (PRO) - Depression symptoms (GAD-2/7) | Change of depression symptoms on each therapy to determine clinical efficacy. This will be done using the GAD-2/7 questionnaire (2 screening questions to determine if symptoms present. If present, 7 additional questions to determine level of depression using a 0 (not at all) - 3 (nearly every day) scale) | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| Patient Reported Outcomes (PRO) - Anxiety symptoms (PHQ-2/9) | Change of anxiety symptoms on each therapy to determine clinical efficacy. This will be done using the PHQ-2/9 questionnaire (2 screening questions to determine if symptoms present. If present, 9 additional questions to determine level of anxiety using a 0 (not at all) - 3 (nearly every day) scale) | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |
| WHO functional class | Change on each therapy to determine clinical efficacy. Functional assessment of PAH will be made according to the WHO classification system: Class I - Patients with PAH without limitation of physical activity. Ordinary physical activity does not cause increased dyspnoea or fatigue, chest pain, or near syncope / Class II - Patients with PAH resulting in slight limitation of physical activity. No discomfort at rest. Normal physical activity causes increased dyspnoea or fatigue, chest pain, or near syncope / Class III - Patients with PAH resulting in marked limitation of physical activity. There is no discomfort at rest. Less than ordinary activity causes increased dyspnoea or fatigue, chest pain, or near syncope / Class IV - Patients with PAH with inability to carry out any physical activity without discomfort. Indications of manifest right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by the least physical activity. | From baseline and area under the curve to 4 weeks, 8 weeks and 12 weeks |